6 FAQ: AUTHORISATION
  6.1 Authorisation procedure
    6.1.1 Is it predictable for industry which substances may be subject to an authorisation? Are the criteria clear enough?
How will PBTs and vPvBs be identified and agreed?
How will “substances of equivalent concern” be identified and agreed?
    6.1.2 Will the authorisation system be unworkable due to the number of substances, uses and enterprises concerned?
    6.1.3 What is ‘adequately controlled’ for the purpose of the granting of authorisations under Article 60(2)?
   
6.1.4
 Can applications for authorisation be submitted together?
   
6.1.5
 How are substances of high concern produced in small volumes treated under REACH?
   
6.1.6
 Decisions on authorisation: what will happen when there is no decision taken by the Commission within the deadline?
   
6.1.7
 Should the applicant always submit a substitution analysis if he decides to submit an SEA (SEA only applicable if there are no suitable alternatives)?
   
6.1.8
 When is it necessary to present a substitution plan?
   
6.1.9
 Role of SEA committee. What does the SEA committee do if it does not receive any input or only input for a SEA. Create its own SEA? What does it do if it receives an SEA which it does not agree with? Can the SEA committee reject a restriction proposal or allow an authorisation in case proper data/analysis is lacking? The very limited time to make a decision should be taken into account when answering these questions.
  6.2 Substitution
   
6.2.1
 How will substitution be promoted?
   
6.2.2
 Substitution will cause additional costs for companies.
   
6.2.3
 How can one be sure that the principle of substitution is not misused under pressure of NGOs?
   
6.2.4
 Worker protection - Can substitution be strengthened?
   
6.2.5
 What will be the content of the substitution plan?
[www.reach-compliance.eu]